{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:01:42Z","timestamp":1789599702777,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":621,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["DK24031"],"award-info":[{"award-number":["DK24031"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["CA183764"],"award-info":[{"award-number":["CA183764"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015724","name":"Mayo Clinic Center for Cell Signaling in Gastroenterology","doi-asserted-by":"crossref","award":["P30DK084567"],"award-info":[{"award-number":["P30DK084567"]}],"id":[{"id":"10.13039\/100015724","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30DK090728"],"award-info":[{"award-number":["P30DK090728"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajp.amjpathol.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ajpath.2017.12.016","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T13:53:17Z","timestamp":1517406797000},"page":"981-994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease"],"prefix":"10.1016","volume":"188","author":[{"given":"Maria","family":"Lorenzo Pisarello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana V.","family":"Masyuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio A.","family":"Gradilone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatoliy I.","family":"Masyuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5386-8810","authenticated-orcid":false,"given":"Jingyi F.","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pui-Yuen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas F.","family":"LaRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2017.12.016_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-9-69","article-title":"Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management","volume":"9","author":"Cnossen","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ajpath.2017.12.016_bib2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.cgh.2016.03.008","article-title":"Polycystic liver disease: the benefits of targeting cAMP","volume":"14","author":"Larusso","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2017.12.016_bib3","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1172\/JCI96729","article-title":"Isolated polycystic liver disease genes define effectors of polycystin-1 function","volume":"127","author":"Besse","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2017.12.016_bib4","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","article-title":"Mutations in GANAB, encoding the glucosidase IIalpha subunit, cause autosomal-dominant polycystic kidney and liver disease","volume":"98","author":"Porath","year":"2016","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ajpath.2017.12.016_bib5","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrgastro.2014.155","article-title":"Polycystic liver diseases: advanced insights into the molecular mechanisms","volume":"11","author":"Perugorria","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2017.12.016_bib6","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ajpath.2017.12.016_bib7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11255-010-9748-1","article-title":"Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease","volume":"43","author":"Peces","year":"2011","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ajpath.2017.12.016_bib8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/MOG.0b013e328343433f","article-title":"Somatostatin analogues for treatment of polycystic liver disease","volume":"27","author":"Gevers","year":"2011","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.ajpath.2017.12.016_bib9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/liv.12986","article-title":"Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis","volume":"36","author":"Gevers","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.ajpath.2017.12.016_bib10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/ndt\/gfq384","article-title":"Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats","volume":"26","author":"Renken","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ajpath.2017.12.016_bib11","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/hep.24723","article-title":"Altered store operated calcium entry increases cyclic 3\u2032,5\u2032-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes","volume":"55","author":"Spirli","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2017.12.016_bib12","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/hep.23511","article-title":"Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice","volume":"51","author":"Spirli","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2017.12.016_bib13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1053\/j.gastro.2009.09.005","article-title":"ERK1\/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice","volume":"138","author":"Spirli","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2017.12.016_bib14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/hep.22636","article-title":"The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD)","volume":"49","author":"Banales","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2017.12.016_bib15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ajpath.2013.11.027","article-title":"HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis","volume":"184","author":"Gradilone","year":"2014","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2017.12.016_bib16","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3\u2032,5\u2032-cyclic monophosphate","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2017.12.016_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.26140","article-title":"Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases","volume":"58","author":"Masyuk","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2017.12.016_bib18","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/j.gastro.2011.11.036","article-title":"Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease","volume":"142","author":"Masyuk","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2017.12.016_bib19","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/hep.29577","article-title":"Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target","volume":"67","author":"Masyuk","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2017.12.016_bib20","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2174\/1389450116666150427161743","article-title":"Therapeutic targets in polycystic liver disease","volume":"18","author":"Masyuk","year":"2017","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.ajpath.2017.12.016_bib21","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.18632\/oncotarget.13738","article-title":"Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ajpath.2017.12.016_bib22","doi-asserted-by":"crossref","first-page":"e0173507","DOI":"10.1371\/journal.pone.0173507","article-title":"Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor","volume":"12","author":"North","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2017.12.016_bib23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13311-016-0501-z","article-title":"Development of improved HDAC6 inhibitors as pharmacological therapy for axonal Charcot-Marie-Tooth disease","volume":"14","author":"Benoy","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ajpath.2017.12.016_bib24","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/hep.29284","article-title":"TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate\/Galphas signaling","volume":"66","author":"Masyuk","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2017.12.016_bib25","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2015.05.023","article-title":"Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease","volume":"63","author":"Munoz-Garrido","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2017.12.016_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajpath.2013.09.021","article-title":"Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression","volume":"184","author":"Masyuk","year":"2014","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2017.12.016_bib27","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1053\/j.gastro.2010.04.010","article-title":"Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD","volume":"139","author":"Gradilone","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2017.12.016_bib28","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.2353\/ajpath.2008.080125","article-title":"Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease","volume":"173","author":"Banales","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajpath.2017.12.016_bib29","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/modpathol.2008.115","article-title":"Disrupted cell adhesion but not proliferation mediates cyst formation in polycystic liver disease","volume":"21","author":"Waanders","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ajpath.2017.12.016_bib30","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.2174\/0929867311320140005","article-title":"Histone deacetylase inhibitors: an attractive strategy for cancer therapy","volume":"20","author":"Li","year":"2013","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ajpath.2017.12.016_bib31","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.21873\/anticanres.11156","article-title":"The effects of histone deacetylase inhibitor and calpain inhibitor combination therapies on ovarian cancer cells","volume":"36","author":"Lapinska","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ajpath.2017.12.016_bib32","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/bjc.2016.36","article-title":"Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia","volume":"114","author":"Ceccacci","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2017.12.016_bib33","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents","volume":"20","author":"Mottamal","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ajpath.2017.12.016_bib34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ki.2011.296","article-title":"Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation","volume":"81","author":"Fan","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ajpath.2017.12.016_bib35","doi-asserted-by":"crossref","first-page":"e0169485","DOI":"10.1371\/journal.pone.0169485","article-title":"Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models","volume":"12","author":"Hennika","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2017.12.016_bib36","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ajpath.2017.12.016_bib37","doi-asserted-by":"crossref","first-page":"19599","DOI":"10.1073\/pnas.0907935106","article-title":"HDAC6 is a target for protection and regeneration following injury in the nervous system","volume":"106","author":"Rivieccio","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2017.12.016_bib38","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1158\/0008-5472.CAN-12-2938","article-title":"HDAC6 inhibition restores ciliary expression and decreases tumor growth","volume":"73","author":"Gradilone","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2017.12.016_bib39","doi-asserted-by":"crossref","first-page":"10885","DOI":"10.1074\/jbc.M111.308791","article-title":"Histone deacetylase 6 (HDAC6) deacetylates survivin for its nuclear export in breast cancer","volume":"287","author":"Riolo","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2017.12.016_bib40","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.kint.2016.01.026","article-title":"Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease","volume":"90","author":"Cebotaru","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ajpath.2017.12.016_bib41","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jaci.2014.10.002","article-title":"Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation","volume":"135","author":"Tsuji","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ajpath.2017.12.016_bib42","doi-asserted-by":"crossref","first-page":"19626","DOI":"10.1038\/srep19626","article-title":"Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of alpha-tubulin acetylation and FGF-21 up-regulation","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpath.2017.12.016_bib43","doi-asserted-by":"crossref","first-page":"22516","DOI":"10.1074\/jbc.M113.489328","article-title":"Inhibition of HDAC6 deacetylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells","volume":"288","author":"Asthana","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2017.12.016_bib44","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1002\/hep.25872","article-title":"Cyclic AMP\/PKA-dependent paradoxical activation of Raf\/MEK\/ERK signaling in polycystin-2 defective mice treated with sorafenib","volume":"56","author":"Spirli","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2017.12.016_bib45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2013.03.004","article-title":"Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial","volume":"59","author":"Chrispijn","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2017.12.016_bib46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1681\/ASN.2013121312","article-title":"Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model","volume":"26","author":"Hopp","year":"2015","journal-title":"J Am Soc Nephrol"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944017307964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944017307964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T23:57:03Z","timestamp":1617235023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944017307964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0002944017307964"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2017.12.016","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2017.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}